The job cuts will affect 49 employees in early research, manufacturing and sales. They will receive severance.
The cuts speak to the high cost of developing drugs, which often is upward of $1 billion, and how companies attempt to spread out the cash among a broad portfolio of programs.
More articles on pharmacy:
Cancer therapy prices prevent access to treatment, WHO says
Despite controversies, J&J ranks among Fortune’s most-admired companies
Bristol-Myers swings to $1.2B profit in Q4
